Nabi’s StaphVAX Development Back On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking a partner for the re-launch of its gram-positive bacteria vaccine program.
You may also be interested in...
Nabi Sells Biologics Business To German Plasma Protein Firm Biotest
Nabi met with FDA Sept. 11 concerning components and a timeline for completion of its Nabi-HB IV BLA, pending at the agency since 2002.
Nabi Sells Biologics Business To German Plasma Protein Firm Biotest
Nabi met with FDA Sept. 11 concerning components and a timeline for completion of its Nabi-HB IV BLA, pending at the agency since 2002.
Nabi Drops StaphVAX Following Failure Of Confirmatory Trial
Firm also halts development of S. aureus immune globulin Altastaph because it uses the same technology as the StaphVax S. aureus vaccine.